drugset
drugset / Trial / NCT03590743

Calf Deep Vein Thrombosis Treatment Trial

NCT03590743 ↗

Phase 4 Terminated 5 enrolled Mayo Clinic Bristol-Myers Squibb · collabPfizer · collab
RandomizedSingle-groupQuadruple-blindTreatment

Summary

The primary objective is to evaluate whether apixaban is more effective in treating patients with isolated calf vein thrombosis (DVT) than serial imaging of the DVT for preventing thrombus spread, pulmonary embolism (PE) and/or recurring DVTs.

Timeline

Start
2019-02-19
Primary completion
2019-06-03
Completion
2019-06-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Apixaban Small molecule 5 mg —

Indications

venous thromboembolism